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Summary. Bone marrow transplantation (BMT) IS the present treatment for
hematological malignancies Two major drawbacks of allogeneic BMT are
graft-versus-host disease (GVHD) and leukemia relapse The use of
HLA-matched siblmgs as marrow donors results m the best transplant out-
come Nonetheless, the results of clmical BMT reveal that the selection of
MHC-identical donors' bone marrow (BM) is no guarantee for avoidmg
GVHD or ensurmg disease-free survival even when donor and recipient are
closely related It is believed that non-MHC-encoded so-called mmor his-
tocompatibility antigens (mHag) are mvolved m both graft-versus-host
and graft-versus-leukemia activities The recent new msights mto the
chemical nature of mHag not only reveal their physiological function but,
more importantly, provide msights mto their role in BMT Together with
the Information on the human mHag genetics and üssue distnbution gath-
ered m the past, we may now apply this knowledge to the benefit of
human BMT Directly relevant is the Utility of mHag molecular typmg for
diagnostics m BM donor selection Most promismg is the use of mHag-
specific cytotoxic Τ cells for adoptive immunotherapy of leukemia
Introduction
Mmor histocompatibility antigens (mHag) are products of
genetic loci responsible for graft rejection As the MHC
encoded major Η Systems, the mmor Η antigens have lmpor-
tant biological functions besides their role in organ and bone
marrow transplantation (BMT) Their latter charactenstic,
however, was first disclosed Both types of transplantation anti-
gens were described by Snell (1) and dissevered from one
another on the basis of their respective power in murme tumor
graft rejection modeis (2) Skm-graftmg expenments m the
mouse demonstrated the presence of a large number of histo-
compatibility antigens coded for by multiple loci scattered all
over the genome They showed distmguishable patterns in ehc-
ltmg allogeneic reaction, skm graftmg over a multiple mmor Η
barrier demonstrated a graft rejection time comparable to those
that differed only at H-2 (2-4)
In human transplantation, donors and recipients are rou-
tmely screened for Identification of the major Η System, there-
fore, graft-versus-host disease (GVHD) and rejection may be
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Toble 1. MHC class I restriction of H-Y-specific cytotoxic and
proliferative T-cell responses
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caused by the dispanty of the products of the mmor Η Systems,
ι e histocompatibility antigens other than those coded for by
the MHC
The descnption by Zinkernagel & Doherty (5) of the clas-
sical lmmunological phenomenon of the MHC-restricted rec
ogmtion of viral antigens by Τ cells appeared also to apply to
the recogmtion of non-MHC alloanügens In the seventies,
murme (6, 7) and human (8, 9) mHag were defined in vitro by
MHC-restricted Τ cells
In man, mHag studies have predommantly been performed
m the HLA-identical BMT settmg The efforts of several investi-
gators have led to the Identification of a relatively small number
of mHag Both cytotoxic Τ cells (CTLs) and T-helper (Th) cells
recognizmg mHag m a classical MHC-restricted fashion were
described MHC molecules serve as templales (10) for peptides
derived from miracellularly processed protems (11, 12) This
knowledge was essenüal for the prediction that mHag are nat-
urally processed fragments of intracelliilar protems that associ-
ate with MHC molecules (13, 14) Indeed, this supposition
was recently venfied both for murme (15) and human mHag
(16)
This review summarizes our current knowledge of the
impact of mHag on the outcome of BMT and discusses the
putative chnical apphcabihties now that biochemical ldentifica-
tion of mHag IS possible
The male-specific mHag H-Y - cellular recogmtion
The mvolvement of H-Y (at that time called Y-factor) m
homograft rejection had been postulated by Eichwald & Shmser
(17) in 1955 The term H-Y antigen was mtroduced by Billmg-
ham & Silvers (18) smce the Y-factor is a transplantation anti-
gen, determmed by a histocompatibihly gene, comparable in
all respects to the antigens responsible for homograft rejection
In vitro immune response agamst the human-male specific
histocompatibility antigen H-Y was detected in a multi-trans-
fused female aplastic anemia patient She received, after anti-
thymocyte globulm (ATG) pretreatment, a bone marrow (BM)
graft, donated by her HLA-genotypically identical male sibling
In vitro analysis of the post-transplant penpheral blood lympho-
cytes (PBLs) of the female patient (HLA phenotype HLA-A2,
A2, B44, B60, Cw3, Cw5, DR4, DRw6) showed unambigu-
ously strong CTL responses specific for male HLA-A2-positive
target cells (8, 9) Whether the Η-Y-speciflc CTLs actually
mediated the allograft rejection, we do not know It must be ,
remarked, however, that most probably the female patient, who
was suffermg from severe aplastic anemia, had been sensitized
to the H-Y antigen prior to transplantation through multiple
blood transfusions and pregnancies Interestmgly, the anü-H-Y
response m the latter patient appeared broader than the
HLA-A2-restncted CD8 CTL clones We isolated two CD4 cyto-
toxic and proliferative H-Y-specific clones one restricted via
HLA-A2 and the other one recogmzed an H-Y T-cell epitope in
association with HLA-B60 (Table 1) (19)
Although m our first case we could not formally prove that
the H-Y-specific CTLs actually mediated the rejection of the
male BM allograft, some years ago we were confronted with a
case with a fatal outcome m which anti-H-Y CTLs were most
probably mainly responsible for BM graft failure It concerned
a multi-transfused female patient suffermg from myelodyspla-
sia after treatment for Hodgkm's disease In vitro analysis prior
to BMT demonstrated the presence of HLA-Al -restricted anti-
H-Y CTLs (Table 1 UPN 4) Smce the father appeared to be the
only HLA-compatible related donor, he was the obvious choice
(despite the presence of the patient's pretransplant anti-H-Y
CTLs) Notwithstandmg intensive pretransplant immunosup-
pressive treatment, there was no recovery of the BM hemato-
poietic function (20) In view of the latter case, expression of
mHag on hematopoieüc stem cells (HPCs) might be lelevant in
presensitized patients receivmg an mHag-positive T-cell-
depleted marrow graft For that purpose, the expression of the
male-specific antigen H-Y was studied for lts expression on
HPCs It became clear that, indeed, H-Y is expressed on CFU-
GEMM, CFU-GM and BFU-E (21) The assumption that H-Y
sensitization can readily occur followmg blood transfusion and
organ transplanlation is based on our subsequenl observations
As shown in Table 1, PBLs derived from three additional cases
showed, after in vitro restimulation with HLA-identical male
cells, exactly the same phenomenon, namely HLA-restricted
(-AI, -A2 and/or -B7) anti-H-Y CTL acüvity In one patient
(Table 1 UPN 5), the H-Y-speafic HLA.-B7-restricted cytotoxic-
lty was delecled shortly after a kidney donated by an HLA-iden-
tical male siblmg acutely rejected (unpubhshed observation)
In circumstances similar to ours, other mvestigator;, have also
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Toble 2. Identification of human mHag
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described the presence of HLA-restncted H-Y-directed cytotox-
lcity (22-24)
To elaborate on the function of the antigen-presentmg
molecule as well as on the antigen recognized, in vitro studies
were carried out with HLA-A2 "variant" molecules and abnor-
mal chromosomal sex patterns, respectively The analysis of the
epitopes on the HLA-A2 molecule reqmred for cellular recog-
nition of the H-Y antigen led to the observations that alloim-
mune HLA-A2-specific CTLs (25, 26) as well as HLA-A2-
restricted H-Y-specific CTLs (27) can distmguish between dif-
ferent HLA-A2 molecules Combmed mvestigations (resultmg
from a collaborative effort) of the HLA-A2-subtype molecules
at the functional level demonstrated that ammo acid changes at
position 43 and m the residues 145-157 (i e cellularly defined
subtypes HLA-A2 2 and HLA-A2 3) lead to the loss of
epitope(s) necessary for assooative recognition of the H-Y
antigen by HLA-A2-restncted CTLs (27, 28) Interestmgly, a
smgle ammo acid change from phenylalamne to tyrosme at
position 9 in the heavy chain of the HLA-A2 molecule (ι e cel-
lularly defined subtype HLA-A2 4) did not affect the recogni-
tion of H-Y by HLA-A2-restncted CTLs (27) These analyses,
carried out well before the crystal structure of HLA-A2 became
available, led us to postulate crucial MHC/peptide-bmdmg Sites
as well as to distmguish harmful from irrelevant ammo acid
changes in the HLA-A2 molecule The Identification of the
HLA-A2-bmdmg H-Y peptide (see below) together with the
availabihty of the HI A-A2 crystal structure ensure that the pos-
tulated MHC/pepude-bmdmg Sites can now be verified
The function and the chromosomal location of the histo-
compatibihty Antigen H-Y were also sought We studied lym-
phocytes frcm mdividuals with a discrepancy between the
karyotype ind phenotypic sex Besides a clear positive reaction
with the cells of an XY female, the H-Y-specific CTLs showed
no reactivity when analyzed agamst XX males (29) Examma-
tion of sex-reversed humans by combmed analyses of different
sets of Y-DNA probes and H-Y-specific CTLs revealed that the
gene for H-Y maps to the long arm or centromeric region of
the human Υ chromosome (30), thereby separatmg the H-Y
gene from the testis-determmmg factor (TDF) locus In addi-
tional studies, it could be shown that a loss of spermatogenesis
did not correlate with absence of the mHag H-Y CTL recogni-
tion, thereby separatmg the azoospermia factor (AZF) locus
from the locus codmg for the mHag H-Y (31) Extensive dele
tion-mappmg studies usrng specific DNA markers revealed that
the H-Y antigen, as determmed by our HLA restncted Η Y-spe
cific CTL clones, maps to a portion of deletion mterval 6 on the
long arm of the human Υ chromosome (32, 33)
The male-specific mHag H-Y - biochemical Identification
Bemg among the H-Y "searchers" smce 1976, we were chal-
lenged to identify the human mHag H-Y The mHag-specific
T-cell clones have been used for the biochemical Identification
of the H-Y peptides The biochemical Isolation procedure, ι e
affinity chromatography combmed with microcapillary
reversed-phase high-performance liquid chromatography
(HPLC) coupled with electrospray lomzation mass spectrome-
try (34), was successfully used for the Identification of the
mHag peptides The H-Y antigen presented by the HLA-B7
molecule was the first one described (35) (Table 2) The
HLA-B7-restncted H-Y T-cell epitope was identified as an 11-
residue peptide derived from the human homologue of the
selected mouse cDNA on the Υ (Smcy) gene (see below)
encoded on the Υ chromosome (35)
The genetic mappmg of the mouse Υ chromosome has
suggested between two and five distmct loci encodmg H-Y
antigens (36) However, a murme H-Y epitope restncted by
H-2Kk has also been shown to be derived from the murme
Smcy protem (37) The demonstration that two H-Y epitopes
from either mouse or human are derived from the same protem
makes SMCY the pnme target in searchmg for other H-Y
epitopes Therefore, we set out to identify the H-Y T-cell
epitope presented by the HLA-A2 molecule Indeed, the H-Y
peptide recognized by our HLA-A2-restncted T-cell clones also
origmates from the SMCY protem (Table 2) (38) Two HLA-A2-
restricted H-Y-specific T-cell clones were used m this study
Immunological Reviews 157/1997 127
Goulmy Minor Η antigens usefui tools for marrow transplantation
1 0 2 10 3 1 0 4 10 5
nM peptide
Fig. 1. Cytotoxic and proliferative HLA-A2 H-Y peptide-specific
responses. Foi both responses, 10,000 responder cells and 50,000 female
stimulator/target cells pulsed with various amounts of Η Υ peptide are
used Effector/target ratios are 11 1 and 18 1 forIR3S andR416,
respectively
S I Stimulation Index (measurement of proliferation)
(Table 1) a CD8 CTL clone (designated as IR35) and a CD4 cyto-
toxic and proliferative T-cell clone (designated as R416) (19),
IR35 and R416 were derived from the same mdividual (Table 1
UPN1) Both clones recognize the 9-residue peptide
FIDSYICQV (Fig 1) with sigmficant cytolytic and proliferative
responses Interestmgly, post-translation modification of this
H-Y epitope significantly altered the recogmtion, especially of
the CD4 H-Y T-cell clone The latter clone clearly preferred the
cystemylated form of the H-Y peptide, whereas the CD8 H-Y
T-cell clone recogmzed both peptide forms equally well (38)
The importance of the SMCY protein as a major source of
H-Y determmants was recently further underlmed Prehmmary
results from a collaborative study (Roosnek et al manuscnpt m
preparation) showed HLA-A2-restncted H-Y reactivity agamst
one dominant H-Y epitope 15 male-specific CTL clones ISO-
lated from 3 mdividuals recogmzed the same HPLC-puriüed
peptide fraction The latter clones all reacted with the
Table 3. No influence of an H-Y mismatch on GVHD. Results of H-Y
typmg accordmg to the GVHD Status m HLA-Al and HLA-A2
donor/recipient pairs
Donor/recipient
pairs
male/male
female/female
male/female
female/male
not tested
total pairs
yes
5
9
8
6
0
28
ΗίΛΑ1
GVHD
no
9
7
1
5
0
22
yes
16
17
18
18
2
71
HLAA2
GVHD
no
11
12
12
10
1
46
FIDSYICQV synthetic peptide, earher identified as the HLA-A2-
restncted H-Y T-cell epitopes derived from SMCY (Table 2) (38)
Simmons et al (39) observed that HLA-B27-presented pep-
tides that are produced and recogmzed m B27-transgemc rats
are not encoded by Smcy, even though the gene seems to be
necessary for their generation Hence, there IS evidence for a
trans-mediated effect of Smcy in givmg rise to these peptides
Interestmgly, additional munne studies demonstrated that H-Y
peptides could be products of genes (other than Smcy) on the
Υ chromosome (40)
The Smcy was earher reported by Agulnik et al as a new
mouse Υ chromosome gene havmg lts human homologue
SMCY mappmg to the same Yq deletion interval as the mHag
H-Y-controllmg locus (41) The latter authors demonstrated
the evolutionary conservation of the Smcy gene by the Isolation
of Smcy homologous from human and horse genomic frag-
ments (41) In view of the latter notion, we mvestigated
whether the mHag are evolutionarily conserved between
human and non-human primates Indeed, human HA-1, HA-2
and H-Y peptides can be recogmzed on the cell surface of
non-human primate cells transfected with human class I genes
by our human HA-1-, HA-2- and H-Y-specific class I-restricted
CTL clones Furthermore, the mH peptides could be eluted
from HLA-A2 1 molecules expressed on the transfected non-
human primate cells This implies that the human mH peptides
have been conserved for at least 3 5 milhon years (42) Indeed,
concurrent with our latter study, Kent-First et al (43) demon-
strated the expression of the SMCY gene m early primate devel-
opment Moreover, the SMCY gene was shown to be widely
expressed (41, 43) This is in concordance with our previous
mHag H-Y tissue distribution studies, wherem we demon-
strated ubiquitous expression of the human mHag H-Y (44)
The precise function of the SMCY gene is still not known It is
expressed very early m embryogenesis (41) SMCY is homolo-
gous to SMCX (located on the X chromosome) at the ammo
acid level at 84 4% (43) SMCY (and SMCX) protems share sig-
mficant sequence homology to retinoblastoma-bmding protein
suggestmg that the SMCY gene may Code for a transcription
factor (43)
The male-specific mHag H-Y — chnical relevance
It has been suggested that GVHD is more frequent in male
recipients of marrow from female donors (45) This effect was
seen primarily with female donors who had been pregnant or
had received a transfusion (45) Indeed, the above-described
H-Y responses (Table 1) were preceded by thorough in vivo sen-
sitization events However, a mismatch for H-Y between donor
128 Immunological Reviews 157/1997
Table 4. Characteristics of HLA class I-restricted mHag
Gouimy Mmor Η antigens useful tools for marrow transplantat on
Restnction molecules
Mendelian segregat on
Phenotype frequency
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'expression on hematopo etic and non hematopoietic cell lineages
bexpression on hematopo etic cell lineages
and recipient, with the H-Y present m the male recipient and
not in the female donor, did not lead to an mcrease in GVHD
in our recent study (46) Table 3 summarizes the results of typ-
mg for H-Y according to the GVHD Status m 50 HLA-Al- and
117 HLA-A2-matched donor-recipient pairs Neither m the
HLA-Al nor in the HLA-A2 pairs IS there a significantly
mcreased frequency of GVHD m the sex mismatch (ι e female
donor/male recipient) combmation
The absence of an H-Y effect was observed earher by Ram-
say et al (47) Also, in zero-mismatched Irving donor renal
transplants, no H-Y effect could be demonstrated (48) Immu-
nodommance amongst the mHag as well as absence of syner-
gistic effects between CTLs and Th cells in mountmg an effi-
cient mHag immune response (as discussed below) may
explam these apparenlly controversial reports
The non-Y-hnked mHag - mHag-specific T-cell subsets
and GVHD
Besides the Y-hnked mHag, one can assume that, as m the
mouse, the human genome has an abundance of mH loci-
encodmg protems that generate mH peptides that are either
processed via the MHC c'ass I pathway or presented m the con-
text of MHC class II Boch mHag-specific class I-restricted CTLs
and class II-restricted Th cells are probably mediating GVHD m
HLA-matched BM transplants In the mouse, a vanety of studies
has been carried out to explore the identity and function of
cells responsible for GVH reacüons After the initial expen-
ments of Boak & Wilson (49), who showed that allogeneic
lymphoid cell populations devoid of donor Τ cells do not
mduce GVHD, and those of Korngold & Sprent (50), who
showed that, by removing mature Τ cells from the marrow,
lethal GVHD across mmor Η barners could be prevented, the
question of which donor T-cell populations are mvolved m the
mduction of GVHD was largely surveyed in the murme model
The T-cell subsets lmtiatmg GVHD can differ for each stram
combmation (51,52) It has also been reported that the Τ cells
mvolved m acute GVHD were found to be different from the
clones estabhshed durmg the chromcphase of die disease (53)
Although CD 8 Τ cells are often reported to be mvolved in
murme GVHD modeis (50, 54), m some stram combmations
CD4 Τ cells can also mediate GVHD (55, 56) Both T-cell sub-
sets have the potential to cause GVHD (57,58) In man, the
presence of a reduced number of CD4 cells in the donor mar-
row moculum appeared to be compatible with slow but sus-
tamed engraftment and a low mcidence of senous acute GVHD
(59) CD8 T-cell depletion m HLA-identical siblmg transplants
reduces the mcidence of GVHD (60, 61) On the other hand, in
vitro observed mHag-specific CTL responses did not necessarily
correlate with the development of human GVHD either on the
bulk or on the CTL precursor frequency level (62, 63) The
same phenomenon was previously noticed in a murme GVHD
model (64) and confirmed on the CTL precursor level as well
(65)
Several reports have demonstated the presence of anti-host
mHag-specific CTLs in patients suffermg from GVHD after HLA-
genotypically identical BMT (62, 66-72) Also, class II-
restricted anti-host CTLs with a CD4 phenotype were observed
m a patient suffermg from severe GVHD after allogeneic BMT
(24) In addition to CTLs, m vitro studies reportmg on host
directed Th cells have been descnbed m patients havmg GVHD
(67, 73-75) Van Eis et al (76) reported on the long-term
kmetics of Th cells in response to host mHag in 16 patients and
demonstrated that sigmficant Th-cell activity in vitro correlates
with chnical acute GVHD These anti-host Th cells carry the CD4
phenotype and recognize mHag in the context of HLA-DR and
-DP (77) Post-transplant host-directed Th-cell responses mea-
sured at the Th-cell precursor level correlate with GVHD (78)
Prior to HLA-identical BMT, putative mHag-specific Th-cell pre-
cursor frequencies can be measured (79, 80) In addition to
anti-host-reactive CD4 Τ cells, IL-2-secreüng CD8 Τ cells are
also detected pnor to HLA-identical siblmg BMT (81)
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Table S. Characteristics of human mHag
References
MHC restncted recognition by Τ cells
presentation via vanous class 1
and class II molecules
Variable phenotype frequencies
Mendelian segregation
Tissue distnbution
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85 90-96
24 747797-99
85 90-99
869092-98
447196100
The non-Y-linked mHag - cellular recognition
Our first non-Y-lmked mHag cellularly identified on the clonal
level origmated from a male acute myelogenous leukemia
(AML) paüent transplanted with BM from an HLA-identical
female siblmg donor His climcal recovery, however, was com-
plicated by severe acute and chronic GVHD The initial experi-
ment demonstrated that the post-transplant lymphocytes had
strong cytotoxic activity agamst the patient's own pretransplant
lymphocytes but not agamst the lymphocytes of his HLA-iden-
tical donor (66) This observation m ltself supporled the
notion that, whatever the target determmant recognized by the
latter CTLs, the HLA-genotypically identical donor and recipi-
ent differed for lt From additional analysis of the patient's post-
transplant CTL activities, lt became apparent that the antigen
(which we designated mHag HA-1) was not only present on
the patient's own pretransplant cells, but could also be detected
on lymphocytes from 2 out of 3 haplo-identical siblmgs, as
well as on the lymphocytes of the parents and on the lympho-
cytes from a large number of unrelated healthy mdividuals The
antigen HA-1 could be recognized by the patient's post-trans-
plant CTLs only lf one of the patient's HLA class I antigens was
present on the target cells (82) Consequently, HA-1 IS recog-
nized in an MHC-restricted fasbion, an event comparable to the
recognition of Η-Ύ With respect to our earher studies on the
impact of sex mismatch in BMT, the in vitro observed CTL
response in this female/male donor-recipient combmation
appeared not to be directed agamst Η-Ύ
Next, we aimed at both confirmation and extension of the
latter results regardmg the possible impact of polymorphic
genetic Systems other than HLA on the development of GVHD
in man For this purpose, we mvestigated post-transplant lym-
phocytes from a series (N=34) of recipients of HLA-identical
BM grafts for the presence of anti-host CTL activity Post-trans-
plani lymphocytes from 21 out of 25 patients suffermg from
GVHD demonstrated CTL activity which was directed agamst
the patient's own pretransplant lymphocytes (83) Host-
directed CTLs could be demonstrated in 6 out of 9 patients suf
fermg from acute GVHD grade 2 or more Furthermore, m 15
out of 16 patients with chronic GVHD, anti-host CTL activity
was also observed lt is worth noting that such CTLs can be
derived from either male or female patients suffermg from dif-
ferent hematologic mahgnancies pnor to BMT Similar to the
initial anti-host-specific CTLs HA-1 (as discussed above), we
next endeavored to uncover the specificity of the target struc
tures recognized by some of the anti host CTLs (Table 4) Five
(including HA-1) out of 21 anti-host CTL populations under-
went comprehensive analyses at the population level as well as
in famihes Comparable to HA-1, anti-host CTLs derived from
the second, third, fourth and fifth patient were found to be
directed agamst rnHag-designated HA-2,-3,-4 and -5, respec-
tively, requirmg self-HLA class I antigens for their recognition
These conclusions are based on the reaction patterns exhibited
by CTLs HA-1 to HA-S agamst a panel of N=100 unrelated
healthy mdividuals
The common denommator of HA-1-, 2-,-4- and -S- spe-
cific CTLs is the preferential use of the MHC class I restriction
molecule HLA-A2 (Table 4) Whether this reflects the relatively
high phenotype frequency of HLA-A2 1 (i e 49% m the Cau-
casian population) or suggests that HLA-A2 1 is optimally
equipped to serve as the template for peptide presentation is
unclear Accordmg to the latter proposition, lt is of mterest to
note that allehc differences exist m the mteraction of
MHC class I molecules with transporters associated with anti-
gen processzng (84) Among other HLA alleles, HLA-A2 shows
that a high affinity for TAP is required for translocation of cyto-
sohc peptides, such as mmor Η peptides, (84a, 84b) In addi-
üon, however, lt is possible that TAP Supports correct folding
and loadmg of a subset of MHC class I molecules (84)
Table 4 also shows the results of the phenotype frequency
analyses carried out for mHag HA-1 to HA-S These studies
revealed that some mHag, ι e HA-1, HA-2 and HA-3, appeared
frequently (69-95%), while others, ι e HA-4 and -5, occurred
with lesser (7-16%) frequencies in the healthy population
(85) An analysis of their genetic traits demonstrated a Mende-
lian mode of mhentance (Table 4) (86) These four antigens can
each be considered as the product of a gene with one allele
expressmg the detected specificity, and one or more alleles not
expressmg lt Although our family data did not provide suffi
cient Information concernmg lmkage between the different
mH loci themselves and HLA, all our tests were compatible
with the hypothesis that these Ion are mdependent of eacb
other and mdependent of HLA (86) The CTL clones hsted in
Table 4 were also used lo analyze functional expression (ι e
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Toble 6. Specificity analysis of mHag-specific CTL clones
UPNa
1
4
5
sex do/rec
female/male
female/female
male/female
CTL lines
HA1
HA 4
HA 5
no of clones
analyzed
7
9
8
10
11
4
11
16
mHag
specificities
HA 1
unknown
HA 4
HA1
unknown
HA 5
HA1
unknown
patients who suffered from severe GVHD
read-out IS cell-mediated-lympholysis) of the mHag on vanous
tissues and cells Differential expression was observed some,
ι e H-Y, HA-3 and HA-4, are ubiquitously expressed, whereas
the expression of other mHag, ι e HA 1 and HA 2, is limited
to cells of the hematopoietic lineage only (44) The additional
Information on the TCR usage for recognizmg the MHC/HA-1
mHag hgand (88) will be touched upon in more detail later in
this paper
In circumstances similar to ours, several other mvestigators
also descnbed the cellular Identification of more (yet a rela
tively small number) non-Y-lmked mHag specificities (for an
overview see (89)) The charactenstics, as presented for H-Y
and HA-1 lo HA-S (Table 4), are repräsentative for other human
mHag identified so far (24, 44, 71, 74, 77, 85, 86, 90-100)
Table 5 summanzes the general features presently known for
human mHag a) recognition by Τ cells in association with var-
IOUS MHC class I and MHC class II molecules, b) occurrence
with variable phenotype frequencies in the random (though
HLA-restricted) population, c) segregation m a Mendelian
fashion, and d) either limited or ubiquitous cell and tissue
expression It is important to note that these conclusions are
drawn from the outcome of functional in vitro cellular assays It
is almost superfluous to State that confirmative studies on the
molecular level need to be carried out
The non-Y-hnkeJ mHag — biochemical Identification
Proteins of (retrc) viral, foreign or self-ongin located m ER,
cytosol or any other organelle can give rise to peptides lmmu-
nogenic to class I-restricted CTLs and can represent transplan-
tation barners (101-105) With respect to the non-Ylmked
classical mHag, the mouse maternally transmitted «mtigen
(Mla) was the first one identified at the molecular level (106)
This milochondrial Η antigen is a peptide derived from the
amino terminus of the ND1 protein (15)
Four alleles have been detected at one locus, each different
by a Single amino acid (106) The first human non-Y-hnked
mHag biochemically identified was HA-2 (16) The HLA-A2-
bound HA-2 peptide most probably originates from an as yet
unidentified member of the non-filament-formmg class I myo-
sin family, a large family of protems that are involved in cell
locomotion and organelle transport (Table 2) At present, we are
mvestigating whether, mdeed, a class I myosm gene is the
source of the HA-2 peptide Identification of the HA-2 gene
will provide the basis for its differential expression in the pop-
ulation (Table 4) Its allehc polymorphism can be a result of pre-
sentation of homologous but non-identical peptides, a failure
to present a peptide because it has lost its MHC-anchor residue
or polymorphism in the class I antigen-processing System The
amino acid sequence of the HA-1 mHag has just been eluci-
dated as well (J Μ Μ Den Haan et al manuscript in prepara-
tion)
The non-Y-linked mHag - clinical relevance
The putative mfluence of known mHag dispanties between
HLA-identical BM donors and recipients on the development of
GVHD has been retrospectively analyzed Elkins et al (107)
analyzed 67 pairs for mcompatibility for mHag Wl in relation
to GVHD No mfluence of Wl on GVHD could be demon-
strated because the number of Wl rmsmatches was too low
(ι e there was a high phenotypic frequency) The study by
Behar et al (108) dealt with allehc differences between donor
and recipient for the polymorphic adhesion molecule CD31
CD3 1 mismatches between BM donor and recipient are associ
ated with an increased nsk of severe GVHD grade 3 or 4
(P=0 004) The platelet-endothehal-cell adhesion molecule 1
(CD31) has a broad expression, and it is constitutively
expressed on vascular endothehal cells, BM stem cells, platelets
and leukocytes (108) Interestmgly, anti-CD31 monoclonal
antibodies seemed to differentially recognize the allehc forms
No CD3 1 -specific T-cell responses were reported, which sepa
rates this transplantation antigen from the classical ones
descnbed in man and rodents earher In a subsequent study
comprising a large series of BM donor/recipient pairs, the pos-
tulated correlation between CD3 1 matches and occurrence of
severe GVHD could not be confirmed (109)
We analyzed the mfluence of mHag HA-1, -2, 4 and -5
mismatches between HLA-identical BM donor/recipient pairs
(i e BM donor mHag-negative and BM recipient mHag-posi-
tive) on the occurrence of acute GVHD grade 2 or more The
results m adult patients can be summarized as follows a mis-
match for HA-1 and/or HA-2, -4, -5 was sigmficantly associ-
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Table 7.
A. HA-1 effect analyzed on GVHD
HA1 #
H A 1 =
Odds ratio
95% confidence interval
Ρ value (2 sided)
Adults and Children
GVHD
no yes
2 11
50 52
54
10 56
005
Adults
GVHD
no yes
0 10
28 43
CO
1 3°o
002
B. No subdominant H-Y effect on GVHD analyzed in 102 HA-1 -
matched patients
GVHD
Η Y #
Η Y =
Odds ratio
95% confidence mterva!
Ρ value (2 sided)
no yes
37 39
13 13
095
0 35 2 55
1000
ated with GVHD (P=0 006) The mam effect of the significant
association with the development of GVHD appeared to be
caused by an HA-1 mismatch, smce a Single HA-1 mismatch
between donor and recipient reached a Ρ value of 0 02 (Table
7Λ) (46) It IS clear that diese studies need confirmation in
larger groups of patients
Immunodominance of mHag
In 1966, Graff, Hildemann & Snell, usmg a panel of congenic-
resistant mice differmg at multiple mH loci, concluded from
their skin allograft studies as followb "The strengths of the barners
imposed by the non H-2 histocompatibility loci were quite variable, the median
survival times for the vanous loci ranging from 15 to > 300 days" (110)
Subsequent senes of murme skin-graftmg responses, in vivo
primmg expenments and GVHD modeis clearly showed that
the immune responses were dommated by a small number of
mHag Hereby the phenomenon of immunodominance of
murme mHag was clearly estabhshed (111-116) Later, the
immunodominance was also verified on the mHag peptide
level Bulk CTL responses generated across multiple mH barn-
ers appeared to be directed againsl only a few mH peptides
(117-120) Whether or not a Single mHag disparity can cause
GVHD, an expenmental condition which will never occur in
man, is not yet clear (121,122)
The fact that a significant number of BM transplants
between HLA-identical sibhngs (with optimal mimunosup-
pression) do not lead to GVHD suggests a hierarchy in mHag
immunogenicity (123) Two sets of our data are mdicative for
mHag immunodominance Firstly, CTL clones reactive to the
same mHag HA-1 were obtamed from peripheral blood lym-
phocytes of 3 mdividuals each transplanted across a multiple and
probably distmct mH barner (Table 6) (85) Secondly, m the study
mentioned earlier of 148 BM HLA-identical donor/recipient
pairs, mvestigatmg the mfluence of mHag HA-1 to HA-5 mis-
matchmg on the development of GVHD, a mismatch of only
HA-1 was sigmficantly associated with GVHD m adult patients
(46)
The hierarchy m mHag immunodominance also imphes
the existence of subdominant mHag, as exemphfied for murme
mHag previously (113) We observed the absence of an H-Y
mismatch effect (discussed above under the headmg The male-
specific mHag H-Y - climcal relevance) (Table 3) In view of the exist-
ence of subdominant mHag, we analyzed our mHag disparities
and human GVHD data by omission of the dominant HA-1
antigen (Table 7)
No H-Y effect could be demonstrated m 102 HA-1-
matched BM donor/recipient pairs (Table 7B) It is of mterest to
note that Wettstein (124) reported on the rmmunodommant
behavior of an autosomal murme mHag H-3 over the H-Y anti-
gen in the generation of CTLs
How to become a "wicked" minor
We now know that mHag are naturally processed protems of
peptidic nature Any protem, whether it is cellular- or mem-
brane-associated, can give rise to mH peptides To become a
"wicked" minor, a condition sme qua non is thdt the minor protem
source must possess some degree of polymorphism The immu-
nogenicity of a potentially large number of mHag is restncted
by vanous factors Some of the possible factors underlymg the
mHag immunodominance, ülustrated by as yet very httle Infor-
mation on human major mmors, will be discussed below
The synergistic effects of MHC class I mHag-specific CTLs and
MHC class II mHag-specific Th cells promotmg an effective
mH immune response
In the murme model, an early report of an effective H-Y
response brought about by H-Y-specific CTLs and Th cell= was
pubhshed by Von Boehmer & Haas (125) Genetic analysis of
loci encoded with the murme H-3 and H-4 regions has
revealed that the existence of separate loci encodmg Th-cell and
CTL mH epitopes was reqmred to mduce a CTL response in vivo,
132 Immunological Reviews 157/1997
Goufmy Minor Η antigens useful tools for marrow transplantation
Ant hostTcell GVHD Status
activities
CTL and Th
CTL alone
Th alone
no CTL no Th
no
2
2
0
3
acute > 2
10
2
1
0
Table 8. Synergistic effects of
mHag-specific CTLs/Th
cells on GVHD
mdicatmg the relevance of Th-CTL cell collaboration m die
anti-H3 and anti-H4 immune response (126, 127) With
regard to the munne mH-H3 complex, recent genetic lmkage
studies demonstrated that the CTL and Th epitope are encoded
by distmct genes, the H3a (encodmg the CTL epitope) and the
H3b (encodmg the Th epitope) map approximately 12 cM
apart on the mouse chromosome 2 (128) Nonetheless, CTL
and Th epitopes can also be encoded by the same gene From a
melanoma patient, CD4 Τ cells isolated from tumor-mfiltratmg
lymphocytes recognized an lmmunodommant epitope coded
for by a gene which also encodes class I CD8 T-cell epitopes
(129) As discussed above (under the heading mHag-specific T-cell
subsets and GVHD), lt IS hkely that both CTL and Th-cell subsets
play a role m the development of human GVHD We analyzed
20 patients to determme whether anti-host CTL and Th-cell
responses occurred simultaneously at different times post-
HLA-identical sibhng BMT Table 8 shows anti-host CTL and Th-
cell responses in 10 out of 13 patients with severe GVHD On
the contrary, in the "no GVHD" group of patients, both CTL
and Th-cell responses were detectable m only 2 out of 7
patients analyzed These prehmmary results support the notion
that CTL and Th mHag epitopes collaborate m the anti-host
GVHD immune responses in man as well Naturally, ldentifica-
üon of the CTL and Th mHag involved m these responses needs
to be determmed
T-cell repertoire dependency
Immunodommance may also depend on the available TCR rep-
ertoire Α smgle murme class I allo peptide appeared dominant
in Vß8-positive but not m Vß8-negative mouse strams, mdicat-
mg that the dominant peptide recogmtion was dependent upon
Vß8-positive Τ cells (130) We observed b^ analyzmg TCR
usage of 12 clones denved from 3 mdividuals (Table 6 UPN 1,
4, S) that the TcRß rhains all used the TCRßV6S9 gene segment
and showed remarkable smularities withm the N-D-N regions
(Table 4) (88)
Peptide affinity
One of the mechamsms of immunodommance also resides at
the level of peptide/MHC-bmdmg properties The affimty of
MHC class I-peptide bmding is crucial for the outcome of an
immune response, even m the Situation of subdominant
epitopes (131) Murme mHag T-cell responses appeared to be
lnfluenced by differential bmding of the minor peptide to
class I molecules (132) Usmg an equilibrium-bmdmg assay to
measure relative affimties, the mHag HA-2 and the H-Y peptide
are classified among the highest affimty naturally processed
peptides that have been identified to date The concentration of
the HA-2 peptide as competitor peptide that resulted m 50%
Inhibition of the lodmated peptide binding (ICSO) was 6 7
nM, and the IC50 value for H-Y was 16 nM (Table 9), the IC50
values for other pubhshed peptides vary from 11—214 nM for
HLA-A2 (133, 134)
Table 9 also ülustrates the half-maximal lysis values of the
human mHag peptides HA-2 and H-Y The synthetic peptide
concentrations reqmred to reconstitute 50% specific CTL rec-
ogmtion are low compared to the values of the T-cell epitopes
reported earher (135) This reflects high affimty of the peptide
for MHC or high affimty of the T-cell receptor
Production of cytokines
Antigen presentation by professional antigen-presentmg cells
(APCs) accounts for the primary mitiation process of GVH
pathogenesis Cytokines do play a sigmficant role in both acute
and chronic GVHD (see (136) for a comprehensive review) In
a murme model, IL-lcc has been postulated as a cntical effector
molecule m mHag-directed GVHD (137) Antibodies to TNFa
could completely prevent lethal GVHD mduced m mH-dispar-
ate mice (138) Also, the GVHD-mducmg potential of some
mH antigen-specific T-cell clones has been shown to correlate
with the levels of TNFa clones produced in vitro (139)
T-cell-derived lymphokmes (IL-3, IL-4, and CSF) are produced
in vivo and in vitro m response to mHag The properties of these
produced activities are similar to those that responded to lrra-
diated syngeneic cells, but there was a difference in the time
course of the lymphokme production between GVH mHag-dis-
parate mice and the syngeneic transplant mice (140)
In man, by means of a GVHD-predictive assay, the in vitro
GVH reacüvity to host skm tissue was found to correlate with
the levels of TNFa and INFy secreted into the supernatant of
HLA-matched patient/donor mixed lymphocyte cultures (141)
Tissue distnbution
Presentation of immunogenic MHC/mH peptide complexes by
Professional APCs is essential for mduction of anti-host cellular
immune responses In this regard, lt is worthwhile mentiomng
that the human mHag HA-1, which is shown to be sigmficantly
associated with GVHD (as discussed earher), is clearly
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expressed on the APCs, ι e dendritic cells (DCs) and Langer-
hans cells (LCs) (142) The latter BM-denved APCs are most
potent m mducmg alloreactive T-cell responses (143, 144)
The conditionmg regime prior to BMT will ehmmate most of
the recipient's hematopoietic cells, yet residual recipient cells
mcludmg DCs can be present Host LCs can persist for a long
time after BMT (145)
Human mHag new concepts for marrow transplantation
and adoptive immunotherapy
The putative clmical potentiahty of mHag IS presently based
upon in vitro results of functional and chnically related studies
performed in the past Beanng this restricted Information m
mmd, three areas of clmical apphcation are worthwhile men-
tiomng (Table 10)
The Utility of diagnostics in BM donor selection is self-evident
Several mHag are now biochemically identified We are cur-
rently identifying the mH genes which will provide us with the
mHag allelic counterparts In the near future, molecular typmg
for mHag loci can be performed Dependmg on how major the
immunodominant mmors turn out to be m the HLA-matched
unrelated donor/recipient combmations, one may consider
overrulmg a mmor-major mismatch The speculative proposal
of the use of immunodominant mHag as GVHD prophylaxis is
based upon putative immunomodulation of the GVHD
response with mHag peptide analogues Designmg mHag pep-
tide analogues which function as MHC or T-cell receptor antag-
omsts might interfere with the harmful anü-host
mHag-directed T-cell reactivities post-HLA-identical BMT The
presence of human mHag peptides in non-human pnmates
(42) could serve as a translational model MHC peptide antag-
omsts will compete for MHC binding Inhibition of secondary
mixed lymphocyte reaction and prevention of murme GVHD
across mH barners by high-affmity class II bmding peptides
were recently demonstrated (146, 147) TCR peptide antago-
nists competmg by their structural similarities for TCR engage-
ments are probably more efficient (148) Whether or not a sm-
gle TCR antagomst can cause sigmficant Inhibition of
mH-direcled T-cell responses is questionable Α major obstacle
is the involvement of the vanous MHC molecules together with
their respective mH allopeptides, not takmg mto account the
possible subdominant mHag responses poppmg up Nonethe-
less, lt is worthwhile analyzmg, once the major mH protein
sources are available, whether at least the harmful mH anti-host
responses can be ekminated Two studies reportmg on adequate
Inhibition of a CTL and a Th-cell response agamst HIV and
TabJe 9. mHag HA-2 and H-Y peptide affinities
A 2 H A 2
A2H Υ
A2 Η Xb
B7H Υ
B7H Χ
IC50 (nM)
67
16
S40
34
140
Half max mal lysis"
40 pM
3pM
not tested
10 pM
100 nM
Reference values 11-214 for HLA A2 10pMtoS0nM
Reconstitution of the HA 2 and Η Υ eptopes wth synthetic peptides indicaton
ofthe synthetic peptde concentraton to achieve 50% iysis wth the mHag specfic
CTL clones
b
 Α homologue of SMCY is SMCX (see underthe heading The male speafic mHag
Η Y-biocbemical identificalion) The amino acid sequence ofthe Η Υ peptide of
SMCY differs only at two amino acid positions from SMCX
influenza hemagglutimn, respectively, with TCR antagomst
peptides (149, ISO) are encouraging
Induction of tolerance usmg mHag with broad tissue
distnbution
Achieving tolerance prior to transplant in mHag-negatrve BM
donors to prevent GVHD and m mHag-negative BM recipients
to prevent rejection would decrease the necessity for the use of
pharmacological immunosuppression
Acquired tolerance for mHag afler MHC-identical BMT
does occur and has been reported in mouse and man
(151-154) Α common denommator in two of the latter
reports (one murme study (152) and one human study (154))
was the involvement of ubiqmtously expressed mHag Induc-
tion of tolerance for mHag m immune mature adults prior to
BMT requires comprehensive analysis Α nice example of
induction of transplantation tolerance for mHag was recently
demonstrated by Davies et al (155) Life-long tolerance for
multiple murme mHag was achieved as a result of suppression
via linked recognition
Adoptive immunotherapy of leukemia
Last but not least, immunotherapy for leukemia usmg CTLs
specific for mHag peptide for the treatment of refraclory, resid-
ual or relapsed leukemia is most promising The mHag with
reslricted tissue distnbution (e g HA-1 and HA-2) are the can
didates for adoptive immunotherapy of leukemia This pro-
posal is supporled by three sets of important clmical results
First, adoptive immunotherapy of buffycoat mononuclear cells
and IFNa mduced cytogenetic remissions in relapsed CML
patients after allogeneic BMT (156-159) However, this donor
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* mHag HA-2-positive EBV-LCLs (n=3)
- φ - mHag HA-2-negative EBV-LCLs + mHag HA-2 peptide
- B - mHag HA-2-positive leukemic cells
- # - mHag HA-2-negative EBV-LCLs (n=3)
Fig. 2. Generation of mHag peptide-specific CTLs. Penpheral
blood lymphocytes were pulsed with the HA-2 synthetic
peptide and used as stimulator cells for autologous Τ cells The
Τ cell lme oblamed was cloned under limitmg dilution
conditions 0 3 cell/well
leucocyte therapy IS associated with a sigmficant occurrence of
marrow aplasia and GVHD (160) In addition, donor leucocyte
infusions for relapsed ALL and AML patients are far less effective
(160, 161) Second, adoptive immunotlierapy with donor
Epstem-Barr virus (EBV)-specific CTLs eradicated EBV-associ-
ated post-transplant lymphoprohferative disease without caus-
mg GVHD (162) Tlurd, adoptive transfer of cytomegalovirus-
specific T-cell clones were effective in restonng immunity
(163)
The advantage of usmg mHag-specific CTLs as adoptive
immunotherapy of leukemia lies m their restricted and specific
target cell damage Thus, we will take advantage of three of the
known characteristics of human mHag (Table 5), ι e
1) MHC-restncted recogmtion by Τ cells, 2) variable pheno-
type frequencies, ι e mHag polymorphism, and 3) restricted
tissue distribution Moreover, smce mHag are clearly expressed
on circulalmg leukemic cells and rlonogenic leukemic precur-
sor cells of both myeloid and lymphoid ongm (164, 16S),
both types of leukemias can be targeted We will generate
mHag peptide CTLs ex vivo from mHag-negative BM donors for
mHag-positive patients Our prehmmary results are promismg
We prepared peplide-specific CTL clones from an HLA-A2-pos-
ltive mHag HA-2-negaave healthy blood donor by pulsmg
autologous APCs with HA-2 synthetic peptide Prohferatmg
clones were expanded and tested for specific cytotoxic acuvHy
agamst mHag HA-2-positive and mHag HA-2-negative EBV-
LCLs and HA-2-negative EBV-LCLs loaded with the HA-2 pep-
tide and agamst mHag HA-2-positive leukemic cells The results
of one mHag peptide-mduced CTL clone are shown in Fijj 2
The results are compared with those obtamed with our pre-
existmg (in vivo mduced) mHag HA-2-specific CTL clone
assayed agamst the same target cells
Upon transfusion (either pre-BMT as part of the condition-
mg regimen or post-BMT as adjuvant therapy), the mHag pep-
tide-specific CTLs will elimmate the mHag-positive patients
leukemic cells and, lf of the patient's origm, also the patients
hematopoietic cells but will spare the patient's non-hematopoi-
etic cells If necessary subsequent mHag negative donor BMT
will restore the patient's hematopoietic System Α universal
Option would be to generate "prefab" mHag peptide-specific
CTLs by usmg mHag-negative healthy blood donors with fre-
quent HLA-homozygous haplotypes Patients who are HA-1 - or
HA-2-positive (and their BM donors HA-1- or HA-2-negative)
and who match the HLA typmg of the CTL donor can be treated
with these "ready to be used" allo HA-1 or HA-2 peptide-spe-
cific CTLs Transduction of these CTLs with a suicide gene
makes ehmmation of the CTLs possible in case adverse effects
occur Future research should also focus on the possible need
for mHag Th epitopes for optimal therapeutic efficacy
Immunodommant mHag
• BM donor selection
• GVHD prophylaxis/treatment
mHag with broad tissue distribution
• mduction of tolerance
mHag with restricted tissue distribution
• adoptive immunotherapy of leukemia
Table 10. Human minor
histocompatibility
antigens: new concepts
for marrow transplantation
and adoptive immunotherapy
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